Movement Disorders

In this video, M. Elizabeth Ross, MD, PhD, FANA, president of the American Neurological Association, spoke with Healio about some of the most memorable sessions from the ANA Annual Meeting and looks ahead to next year’s meeting.

DENVER — Deterioration of memory and executive functions were associated with worsening quality of life for those with Parkinson’s disease over a 3-year period, according to a poster at the American Academy of Neurology annual meeting.

Compared with oral administration, continuous subcutaneous infusion of carbidopa/levodopa was linked to nearly 2 more hours of “on” time without dyskinesia in adults with Parkinson’s disease, data from The Lancet Neurology show.

The FDA has approved a rechargeable deep brain stimulation device with remote programming for individuals living with movement disorders, according to the manufacturer.

According to results of a recent survey, more than 80% of U.S.-based neurologists agreed that a major unmet need in confronting Huntington’s disease is halting neurodegeneration prior to the onset of symptoms.

The FDA has accepted a new drug application from Karuna Therapeutics for KarXT, an investigational muscarinic antipsychotic for the treatment of schizophrenia in adults, the company announced in a press release.

Neurocrine Biosciences Inc. recently presented data on comorbidities, polypharmacy and treatment patterns of patients prescribed benztropine who also were being treated with antipsychotic medications.

CHICAGO — Stephen Reich, MD, professor of neurology at the University of Maryland School of Medicine in Baltimore, spoke at ANA 2022 about clinical features of functional movement disorders and how to best identify them.

CHICAGO – Mark Hallett, MD, chief of the motor control section at NINDS, discussed the pathology and etiology of functional neurological movement disorders at ANA 2022.